Skip to content

Incyte INCY Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Pfizer logo
PfizerPFE
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
Gilead Sciences logo
Gilead SciencesGILD
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$23.51B+73.1%
Enterprise value$19.56B+67.7%
P/E14.6×-1.0×
P/S+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's deferred tax assets and other non-current assets?
Incyte (INCY) reported deferred tax assets and other non-current assets of $86.76M in Q2 2026.
How has Incyte's deferred tax assets and other non-current assets changed year-over-year?
Incyte's deferred tax assets and other non-current assets increased by 166.5% year-over-year, from $32.55M to $86.76M.
What is the long-term trend for Incyte's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Incyte's deferred tax assets and other non-current assets has grown at a -15.2% compound annual growth rate (CAGR), from $41.46M to $18.17M.